HeartSciences (HSCSW) EBIT Margin (2021 - 2025)

HeartSciences (HSCSW) reported EBIT Margin of 85713.23% for Q4 2025, up 13.1% quarter-over-quarter from 98637.84% in Q3 2025.

HeartSciences (HSCSW) EBIT Margin (2021 - 2025) Analysis & Trends

HeartSciences has reported EBIT Margin for 5 years, with the latest figure at 85713.23% in Q4 2025.

For the quarter ending Q4 2025, EBIT Margin changed N/A year-over-year to 85713.23%; the trailing twelve-month figure through Jan 2026 stood at 89939.57% (down 4525160.0% YoY), and the FY2025 full-year result was 192013.13%, down 15811114.0% from the prior year.
EBIT Margin for Q4 2025 stood at 85713.23%, up from 98637.84% in the prior quarter.
The five-year high for EBIT Margin was 9011.84% in Q3 2021, with the low at 98637.84% in Q3 2025.
Historically, EBIT Margin has averaged 48780.2% across 5 years, with a median of 44418.82% in 2025.
Annual changes were most pronounced in 2022 — EBIT Margin tumbled 3567869 bps — and 2024, when it surged 5676700 bps.
HeartSciences' EBIT Margin stood at 9011.84% in 2021, then sank by 396 bps to 44690.53% in 2022, then increased by 10 bps to 40254.95% in 2023, then soared by 74 bps to 10376.75% in 2024, then slumped by 726 bps to 85713.23% in 2025.
The last three EBIT Margin figures came in at 85713.23% (Q4 2025), 98637.84% (Q3 2025), and 44147.1% (Q2 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	12.05%
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	15.55%
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	16.24%
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	21.16%
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	28.97%
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	6.17%
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	21.42%
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	10.04%
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	19.94%
10	HeartSciences	-	-	-	-

Download Data